Mathiesen O, Wetterslev J, Kontinen V K, Pommergaard H-C, Nikolajsen L, Rosenberg J, Hansen M S, Hamunen K, Kjer J J, Dahl J B
Section of Acute Pain Management, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Acta Anaesthesiol Scand. 2014 Nov;58(10):1182-98. doi: 10.1111/aas.12380. Epub 2014 Aug 13.
Post-operative pain affects millions of patients worldwide and the post-operative period has high rates of morbidity and mortality. Some of this morbidity may be related to analgesics. The aim of this review was to provide an update of current knowledge of adverse events (AE) associated with the most common perioperative non-opioid analgesics: paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GCCs), gabapentinoids and their combinations. The review is based on data from systematic reviews with meta-analyses of analgesic efficacy and/or adverse effects of perioperative non-opioid analgesics, and randomised trials and cohort/retrospective studies. Generally, data on AE are sparse and related to the immediate post-operative period. For paracetamol, the incidence of AEs appears trivial. Data are inconclusive regarding an association of NSAIDs with mortality, cardiovascular events, surgical bleeding and renal impairment. Anastomotic leakage may be associated with NSAID usage. No firm evidence exists for an association of NSAIDs with impaired bone healing. Single-dose GCCs were not significantly related to increased infection rates or delayed wound healing. Gabapentinoid treatment was associated with increased sedation, dizziness and visual disturbances, but the clinical relevance needs clarification. Importantly, data on AEs of combinations of the above analgesics are sparse and inconclusive. Despite the potential adverse events associated with the most commonly applied non-opioid analgesics, including their combinations, reporting of such events is sparse and confined to the immediate perioperative period. Knowledge of benefit and harm related to multimodal pain treatment is deficient and needs clarification in large trials with prolonged observation.
术后疼痛影响着全球数百万患者,术后阶段的发病率和死亡率很高。其中一些发病情况可能与镇痛药有关。本综述的目的是更新与最常见的围手术期非阿片类镇痛药相关的不良事件(AE)的现有知识:对乙酰氨基酚、非甾体抗炎药(NSAIDs)、糖皮质激素(GCCs)、加巴喷丁类药物及其组合。该综述基于对围手术期非阿片类镇痛药的镇痛效果和/或不良反应进行系统评价和荟萃分析的数据,以及随机试验和队列/回顾性研究的数据。一般来说,关于不良事件的数据稀少,且与术后即刻阶段有关。对于对乙酰氨基酚,不良事件的发生率似乎微不足道。关于非甾体抗炎药与死亡率、心血管事件、手术出血和肾功能损害之间的关联,数据尚无定论。吻合口漏可能与非甾体抗炎药的使用有关。没有确凿证据表明非甾体抗炎药与骨愈合受损有关。单剂量糖皮质激素与感染率增加或伤口愈合延迟无显著相关性。加巴喷丁类药物治疗与镇静增加、头晕和视觉障碍有关,但临床相关性需要进一步阐明。重要的是,关于上述镇痛药组合的不良事件的数据稀少且尚无定论。尽管最常用的非阿片类镇痛药(包括其组合)存在潜在不良事件,但此类事件的报告稀少,且仅限于围手术期即刻。关于多模式疼痛治疗的利弊的知识不足,需要在长期观察的大型试验中加以阐明。